BridgeBio Pharma (BBIO) Other Non-Current Liabilities (2018 - 2026)

BridgeBio Pharma has reported Other Non-Current Liabilities for 9 years, with the latest figure at $229000.0 in Q1 2026.

• Quarterly Other Non-Current Liabilities fell 34.94% year-over-year to $229000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $229000.0 (down 34.94% YoY) and the FY2025 annual result came in at $244000.0, down 14.69% from the prior year.
• Other Non-Current Liabilities slipped to $229000.0 in Q1 2026 per BBIO's latest filing, from $244000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $28.6 million in Q2 2022 and troughed at $229000.0 in Q1 2026.
• A 5-year average of $9.6 million and a median of $679000.0 in 2025 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2024: Other Non-Current Liabilities jumped 131.05% in 2022, then sank 96.8% in 2024.
• Over 5 years, Other Non-Current Liabilities stood at $26.6 million in 2022, then sank by 78.85% to $5.6 million in 2023, then slumped by 94.92% to $286000.0 in 2024, then declined by 14.69% to $244000.0 in 2025, then fell by 6.15% to $229000.0 in 2026.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $229000.0, $244000.0, and $679000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.